Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 14, 2007
Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humansBindhu Karanam, Maria Madeira, Scott Bradley, et al.Journal of Clinical Pharmacology|March 11, 2015
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of ageMatthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, et al.The Lancet. Infectious Diseases|June 18, 2013
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trialMark Sulkowski, Stanislas Pol, Josep Mallolas, et al.Journal of Clinical Pharmacology|November 14, 2018
Population Pharmacokinetic Modeling to Evaluate Standard Magnesium Sulfate Treatments and Alternative Dosing Regimens for Women With PreeclampsiaLihong Du, Larissa Wenning, Elizabeth Migoya, et al.American Journal of Therapeutics|May 13, 2009
Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiencyMark Stroh, Larissa Wenning, Wen-Lin Luo, et al.Journal of Clinical Pharmacology|September 29, 2020
Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With RifabutinKa Lai Yee, Tamara D Cabalu, Yuhsin Kuo, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsMartin Markowitz, Javier O Morales-Ramirez, Bach-Yen Nguyen, et al.Journal of Clinical Lipidology|February 5, 2011
Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humansEseng Lai, M Gerard Waters, James R Tata, et al.European Journal of Drug Metabolism and Pharmacokinetics|December 17, 2017
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic ImpairmentWilliam L Marshall, Hwa-Ping Feng, Larissa Wenning, et al.Pageof 4